Perspective Therapeutics, Inc. (CATX) is a clinical-stage radiopharmaceutical company with no commercial revenue from drug programs. Under a liquidation lens as of December 31, 2025, equity recovery is deeply negative. Total assets are $267.0M against total liabilities of $59.9M, yielding GAAP book equity of approximately $207.0M. However, applying liquidation haircuts collapses this materially. Cash and cash equivalents of $30.6M recover at 100%. Short-term investments (available-for-sale debt securities) of $114.1M recover near par given current fair value approximates amortized cost ($114.0M). Accounts receivable are negligible at $6K. Property, plant and equipment gross of $82.8M with accumulated depreciation of $6.2M yields net book value of $76.6M; at a 50-60% recovery rate, realizable value is roughly $38-46M. This asset base is dominated by three buildings acquired in 2024 for manufacturing buildout (Houston TX, Chicago IL, Los Angeles CA), which are early-stage construction projects with limited alternative-use value and likely sit at the low end of the recovery range. Intangible assets net of $0.4M (finite-lived) plus $40.0M indefinite-lived intangibles (in-process IPR&D) recover at 0% under liquidation conventions, destroying $40M of book value. The $10.0M intangible impairment booked in 2025 (tagged ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill) signals the carrying value of remaining indefinite-lived intangibles is already under pressure. Deferred income noncurrent of $26.6M (primarily the Lantheus Option Agreement payment) is a liability at face value that does not extinguish on liquidation. The Thorium-228 take-or-pay commitment with the DOE of approximately $8.4M and the approximately $27.5M building modification contract (entered October 2025) represent production and construction commitments that persist on wind-up and are not captured in the GAAP liability stack; these are disclosed in MD&A/commitments footnote but the building modification estimate ($27.5M) is not separately XBRL-tagged. Net operating cash burn was $82.5M for FY2025 versus $57.8M for the nine months ended September 30, 2025 per the prior 10-Q, indicating accelerating cash consumption. The February 2026 public offering raised approximately $175.0M gross proceeds post-period end, materially improving the cash position after the balance sheet date but not reflected in the December 31, 2025 balance sheet. Cumulative accumulated deficit stands at $334.8M. Full valuation allowance maintained against net deferred tax assets; no tax shield value recoverable. MFFAIS liquidation values (CLV/LLV/OLV all approximately -$0.7M) are directionally consistent with a near-zero or marginally positive equity recovery after haircuts on PP&E and zeroing intangibles, offset partially by the large liquid investment portfolio.
▼ Community Notes